Tilapia lake virus (TiLV) poses a major threat to global tilapia aquaculture and contributes to significant economic losses due to the absence of effective vaccines and treatments. Given the high mortality rates and severe pathological effects of TiLV on tilapia, alternative strategies, such as immunoglobulin-based therapies, are being considered for disease control. In this study, we developed specific immunoglobulin Y (IgY) antibodies against TiLV and evaluated their neutralization activity. Laying hens were immunized via intramuscular injections of recombinant TiLV segment 4 protein, and IgY antibodies were extracted and purified from their egg yolks using polyethylene glycol precipitation. Western blot analysis confirmed the specificity of the IgY, which demonstrated no cross-reactivity with nontarget proteins. Neutralization assays revealed a dose-dependent reduction in TiLV infectivity, which declined from 5.01 × 10⁶ TCID₅₀/mL to 5.01 × 10⁴–1.26 × 10⁵ TCID₅₀/mL, with the highest efficacy observed at a 1:2 dilution. Despite the variability in neutralization infectivity among the different hens, IgY effectively inhibited TiLV-induced cytopathic effects. Immunofluorescence assays further confirmed a significant reduction in the TiLV antigen levels in IgY-treated RHTiB cells. Our findings highlight IgY as a promising strategy for TiLV control and suggest its potential application in the prevention of emerging viruses.

Effective surveillance of viral disease in fish populations is critical for disease control and the sustainable development of global aquaculture. Here, we evaluated the application and performance of pooled serum samples using an indirect ELISA based on recombinant segment 4 protein to assess farm-level immunity in tilapia infected with Tilapia lake virus (TiLV). The TiLV-S4 ELISA was developed using a recombinant nucleoprotein (segment 4) antigen, optimized through checkerboard titration, and validated for repeatability and reproducibility, with intra- and inter-assay coefficients of variation below 10%. A pooling strategy was used to combine multiple serum samples before testing for the presence of TiLV-specific antibodies using an enzyme-linked immunosorbent assay (ELISA). Our results showed that pooling five serum samples was effective for detecting TiLV-specific antibodies, particularly when multiple seropositive individuals were presented in the pool, supporting its application for population-level surveillance. However, ELISA sensitivity may be reduced when only one seropositive sample is included in the pool, due to the dilution effects. Despite this limitation, pooled testing yielded a high proportion of positive results, suggesting similar detection performance in many cases. Overall, the pooling strategy provides a cost-effective and time-efficient approach for large-scale monitoring of immune status in tilapia populations.